Menu Search
Equities

Daiichi Sankyo Co Ltd

D4S:DUS

Daiichi Sankyo Co Ltd

Actions
  • Price (EUR)29.66
  • Today's Change0.530 / 1.82%
  • Shares traded570.00
  • 1 Year change+18.69%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 18:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.

  • Revenue in JPY (TTM)1.76tn
  • Net income in JPY250.40bn
  • Incorporated2005
  • Employees18.73k
  • Location
    Daiichi Sankyo Co LtdDaiichi Sankyo Bldg. A/B Kan3-5-1, Nihombashi Hon-choCHUO-KU 103-8426JapanJPN
  • Phone+81 362251111
  • Websitehttps://www.daiichisankyo.co.jp/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.